Pharma

Your Article Summary

See Latest Articles

Myriad Genetics Announces Preliminary Revenue Results for Fiscal 2009 Fourth Quarter, Full Year
Myriad, 07/30/09

Myriad Genetics, Inc. announced that, based on preliminary estimates, it anticipates reporting total molecular diagnostic revenue, which represents the bulk of the Company's revenue, of approximately $86 million for the fiscal 2009 fourth quarter ending June 2009. The Company continues to believe that revenue for the fiscal 2009 fourth quarter is being impacted by the current economic recession, which is driving increasing unemployment levels resulting in the loss of insurance coverage and patients delaying or cancelling doctor visits.

Today in Financial Reports...keeping you current

Receive free subspecialty "5-minute updates" via email

Abbott Declares 344th Consecutive Quarterly Dividend
Abbott, 12/15/09

Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering
Dendreon Coproration, 12/15/09

Pre-Budget Report response - GSK comments on patent box
GlaxoSmithKline, 12/11/09

 See all of Financial Reports